Ruty Ben Shlomi - 03 Sep 2026 Form 3 Insider Report for CollPlant Biotechnologies Ltd (CLGN)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
19 Oct 2026, 16:15:23 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ruty Ben Shlomi
Filing notes and source

Key filing fact

Ruty Ben Shlomi filed Form 3 for CollPlant Biotechnologies Ltd (CLGN) on 19 Oct 2026.

Key facts

  • This page summarizes Ruty Ben Shlomi's Form 3 filing for CollPlant Biotechnologies Ltd (CLGN).
  • 0 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 19 Oct 2026, 16:15.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002154341 Primary reporting owner

Shlomi Ruty Ben

Relationship
Director
Address
C/O COLLPLANT BIOTECHNOLOGIES LTD., 4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK, REHOVOT, ISRAEL
Signature
/s/ Ruty Ben Shlomi
Signature date
19 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLGN holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
66,501
Date
03 Sep 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLGN holding Derivative

Pre-Funded Warrants to Purchase Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
03 Sep 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
105,038
Exercise price
$0.000100
Footnotes
F1, F2
CLGN holding Derivative

Milestone Pre-Funded Warrants to Purchase Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
03 Sep 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
3,999,446
Exercise price
$0.000100
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the "Reverse Stock Split"). The amount of securities reported on this Form 3 has been adjusted to reflect the Reverse Stock Split.

Footnote F2

The Pre-Funded Warrants remain exercisable until fully exercised.

Footnote F3

The Milestone Pre-Funded Warrants become exercisable upon their issuance, subject to the achievement of specified business milestones, and remain exercisable until fully exercised. The Milestone Pre-Funded Warrants are exercisable for up to an aggregate of 3,999,446 ordinary shares, no par value, of the Issuer (the "Ordinary Shares"), with the first tranche, covering 441,683 Ordinary Shares, becoming exercisable upon achievement of the first milestone; the second tranche, covering 1,718,726 Ordinary Shares, becoming exercisable upon achievement of the second milestone; and the third tranche, covering 1,839,037 Ordinary Shares, becoming exercisable upon achievement of the third milestone, in each case subject to the terms and conditions of the Milestone Pre-Funded Warrants.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .